DPP4 and metabolic syndrome: The crude HR (SGLT2 vs DPP-4 inhibitors as a reference group) was 0.88 (0.76–1.02) and the aHR in model 3 (based on an inverse probability weighting of propensity score calculated from age, sex, year, and drugs for hypertension, dyslipidemia, and hyperuricemia) was 0.94 (0.80–1.11) (Table 3).